Skip to main content



29-11-2022 | Diabetes | News | Article

Call to rethink CGM advice for older adults

Analysis of participants in the ORACL trial leads researchers to suggest that nonfrail older adults with type 1 diabetes are better off following time in range guidance aimed at younger people.

29-11-2022 | Rheumatology | News | Article

The metabolic syndrome may influence the risk for gout

The metabolic syndrome may be a modifiable risk factor for incident gout, suggest findings from a nationwide study of more than 1.29 million men.

28-11-2022 | Rheumatology | News | Article

Treatment goals in late-onset RA should match those for younger patients

People with late-onset rheumatoid arthritis have a similar likelihood of achieving remission as those with earlier-onset disease, indicating that treatment goals should be the same in both populations, researchers report.

28-11-2022 | Oncology | News | Article

Cancer screening uptake fails to return to prepandemic rates

The rates of population-based screening and diagnosis of breast, cervical, and colorectal cancer in the USA in 2021 remained below those reported before the COVID-19 pandemic, researchers caution in JAMA Oncology.

25-11-2022 | Oncology | News | Article

GIM2 defines ‘optimal’ high-risk early breast cancer adjuvant chemotherapy

End-of-study findings from the GIM2 trial indicate that adjuvant anthracyclines plus taxane chemotherapy for high-risk early breast cancer should be given in a dose-dense regimen and should not include fluorouracil.

24-11-2022 | Diabetes | News | Article

STANDby confirms diabetes remission with weight loss in South Asian population

Following a very-low-calorie total diet replacement plan can lead to type 2 diabetes remission in South Asian individuals, shows the STANDby trial.

24-11-2022 | Neurology | News | Article

FIREFISH 2-year data show continued benefit of risdiplam for type 1 SMA

The 24-month results from part 2 of the open-label FIREFISH trial suggest that prolonged treatment with risdiplam is associated with continued improvements in motor function and development in infants with type 1 spinal muscular atrophy.

This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.

23-11-2022 | Rheumatology | News | Article

LOUiSSe study shows remibrutinib efficacy in Sjögren’s syndrome

Remibrutinib, an oral Bruton’s tyrosine kinase inhibitor, has shown potential for the treatment of Sjögren's syndrome in a phase 2 study.

23-11-2022 | Oncology | News | Article

MRE11 expression may serve as prognostic biomarker in nonmetastatic MIBC

Normalized expression levels of the DNA repair protein MRE11 could help to identify patients with nonmetastatic muscle-invasive bladder cancer likely to benefit from bladder-preserving trimodality therapy, suggests research.

22-11-2022 | Diabetes | News | Article

FDA clears dulaglutide for adolescents

Click through to read more on this announcement

21-11-2022 | Diabetes | News | Article

Type 2 diabetes linked to advanced stage at cancer diagnosis

Having type 2 diabetes increases a person’s risk for a cancer being already metastatic at the point of diagnosis, shows an EPIC analysis.

21-11-2022 | Rheumatology | News | Article

Abortion restrictions impede methotrexate access for some rheumatology patients

Patients with rheumatic diseases have reported issues with access to methotrexate following changes to abortion laws, show findings from a questionnaire study conducted in the USA.

21-11-2022 | Oncology | News | Article

Add-on olaparib receives EMA backing for untreated metastatic CRPC

More details about this decision available here

18-11-2022 | Diabetes | News | Article

FDA clearance for teplizumab to slow type 1 diabetes onset

Click through to read more on this announcement

18-11-2022 | Diabetes | News | Article

Dapagliflozin HFpEF benefits independent of glucose levels

People who have heart failure with preserved ejection fraction benefit from dapagliflozin irrespective of whether they have normal or impaired glucose metabolism, shows further analysis of DELIVER.

18-11-2022 | Rheumatology | News | Article

A Great Debate: To treat or not to treat in pre-RA?

In one of two Great Debate sessions at ACR Convergence 2022 in Philadelphia, Pennsylvania, USA, two experts teamed up to provide opposing stands on whether now is the right time to be treating people at risk for rheumatoid arthritis in the preclinical stages of the condition in order to prevent disease onset.

17-11-2022 | Rheumatology | News | Article

Secukinumab comparable to adalimumab biosimilar in axSpA

Researchers have found that secukinumab performs equally well to adalimumab biosimilar for the treatment of radiographic axial spondyloarthritis in a head-to-head trial.

17-11-2022 | Paediatrics | News | Article

Kawasaki disease incidence during COVID-19 sheds light on pathogenesis

Data from a nationwide hospital survey show a marked decrease in the incidence of Kawasaki disease in Japan in 2020 compared with the previous year, with differences in patterns of reduction between children younger than 12 months and those aged 24 months or more.

This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.

17-11-2022 | Oncology | News | Article

FDA approves durvalumab, tremelimumab, chemo triplet for metastatic NSCLC

Click through for more information about this decision

17-11-2022 | Rheumatology | News | Article

New score could predict ILD development in people with SSc

Researchers have developed the ILD-RISC score, which has the potential to predict the development of interstitial lung disease in patients with systemic sclerosis.